Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 9/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77101 | 0.83 | — | — | |
| SCHEMBL5387 | 0.83 | — | — | |
| SCHEMBL1706403 | 0.83 | MEN1 (0.39) | OPRD1HRH3SIGMAR1SLC6A2SLC6A4 | |
| Iodide SCHEMBL30375035 | 0.81 | MEN1 (0.38) | OPRD1HRH3SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL12403231 | 0.81 | MEN1 (0.38) | HRH3SIGMAR1SLC6A2SLC6A4CHRM5 | |
| Hydrochloric Acid SCHEMBL522550 | 0.81 | MEN1 (0.38) | HRH3SIGMAR1SLC6A2SLC6A4CHRM5 | |
| SCHEMBL4822887 | 0.81 | MEN1 (0.38) | HRH3SIGMAR1SLC6A2SLC6A4CHRM5 | |
| SCHEMBL13509549 | 0.81 | MEN1 (0.38) | HRH3SIGMAR1SLC6A2SLC6A4CHRM5 | |
| Hydrochloric Acid SCHEMBL1742546 | 0.81 | MEN1 (0.38) | HRH3SIGMAR1SLC6A2SLC6A4CHRM5 | |
| Piperazine SCHEMBL28179364 | 0.81 | MEN1 (0.38) | HRH3SIGMAR1SLC6A2SLC6A4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585073-B1 | ANTIVIRAL COMPOUNDS | PROSETTA ANTIVIRAL INC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-8785434-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2585073-A1 | ANTIVIRAL COMPOUNDS | Prostetta Antiviral Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| CN-102958525-A | Antiviral compounds | PROSTETTA ANTIVIRAL INC | 2013-03-06 | — | — | CN | disclosed |
| US-20120157435-A1 | Antiviral Compounds | PROSETTA ANTIVIRAL INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011137447-A1 | ANTIVIRAL COMPOUNDS | PROSTETTA ANTIVIRAL INC. (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157435-A1 | Antiviral Compounds | MAVS, ZC3HAV1, EIF2AK2 | OPRD1 3667/4885HRH3 3258/4885SIGMAR1 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.